Advocacy & Practice Updates — Clinical Updates
Prompted by ASRS, UHC Agrees to Keep Eylea HD
In a win for physician and patient access, ASRS provided information to compel UHC to pause its plan to remove access to Eylea HD for its commercial patients. As reported last month, UHC had plans to suspend access to Eylea HD for its commercial patients starting October 1. UHC has decided to hold off on the change and will further review its position on providing access. In the meantime, Eylea HD will remain on its “Review at Launch” Medical Drug list, which strongly encourages providers to seek a pre-determination to ensure its coverage. If you are aware of access issues impacting retina patients, please contact us.
Published September 10, 2024